Allergan, the maker of Botox®, recently launched a new dermal filler, Juvéderm® HYDRATE. The latest filler contains both Hyaluronic acid (HA) and the anti-oxidant mannitol. Juvéderm® HYDRATE, which was given a European CE mark in late 2009, is clinically proven to both hydrate and plump skin when injected into the neck, face and décolletage areas.
According to Cosmetic Surgery Times, Dr. Maryna Taieb presented the findings on Juvéderm® HYDRATE at the 8th Anti-Aging World Congress in Monte Carlo, Monaco. The two-month long study followed 27 female patients who were injected in the face, neck and décolletage areas. Doctors assessed the patients’ skin for texture, brightness, hydration and appearance on days 15, 30, and 60.
At the end of the study, 95% of treated patients were pleased with their results and 85% said that they would recommend Juvéderm® HYDRATE to a friend.
Results presented by Paris-based Dr Maryna Taieb at the 8th Anti-Aging World Congress in Monte Carlo, showed that 95% of patients treated with Juvéderm® HYDRATE were pleased with the results of their treatment and 85% said they would recommend the treatment to a friend. Not only that, but 80% of patients showed significant improvement in their skin after day 60.
According to Dr. Taieb: “Juvéderm® HYDRATE allows physicians to deliver a deeply hydrating boost of HA to the skin which helps restore the skin’s healthy glow. Deep hydration is key to keeping skin looking younger for longer, as well as helping to prevent wrinkles.”
Juvéderm® HYDRATE is not yet approved by the FDA to be used in the U.S. market; however, it is currently available across much of Europe. Perhaps this advancement in dermal fillers will set a new standard for future products to come.
To Your Health & Beauty,
Kent V. Hasen, M.D.